Theranostic nanoparticles combined radiation therapies

About

Radiotherapy is used for 50% of the cancer treatments. Despite important technological improvements, secondary effects remain significant due to lack of tumor selectivity and/or radioresistance. A new strategy combining radiation with tumor targeted nanoagents to improve tumor diagnostic and therapeutic index of radiations has emerged.  The potential of platinum nanoparticles will be presented.

Bio

Sandrine LACOMBE is full professor at U.Paris Saclay, an expert in the development of theranostic nanoparticles for radiation therapies. She is leading a research group in the Institute of Molecular Sciences (CNRS). She obtained her PhD in science at U Paris Sud and she performed a postdoc with a Fritz-Haber fellowship in the group of Prof Ertl, Nobel Prize 2007, at the Fritz-Haber Institut Berlin, Germany. She was invited to be a researcher at the Sherbrooke University Hospital (Canada), the nuclear center of Bariloche (Argentina) and the Sydney University (Australia).  She is leading the interdisciplinary institute for innovative radiation strategies, iNanotheRad, which merges the community of radiooncologists, medical physicists, chemists, biologists, physicists, engineers of Paris Saclay. 

Hosted by Yolanda Prezado. New Approaches in Radiotherapy Group, CiMUS

Certificates of attendance will be provided upon request to cimus.xestion [at] usc.es (cimus[dot]xestion[at]usc[dot]es). Please do not forget to enter your name and surname on the printout. If you fail to do so, we will not be responsible for changing anyone's record